Talk:Aripiprazole: Difference between revisions
>Blackhole m 0xea moved page Aripiprazole to Talk:Aripiprazole: moving to "talk" namespace for visibility |
>Blackhole m 0xea moved page Aripiprazole to Talk:Aripiprazole: moving to "talk" namespace for visibility |
(No difference)
| |
Revision as of 02:39, 6 October 2023
Aripiprazole (branded as Abilify, Aristada among others) is an atypical antipsychotic approved for the treatment of schizophrenia, psychosis, bipolar disorder, and along with an antidepressant to treat major depressive disorder.
Aripiprazole was developed by "Ostuka-group" from Japan as an improvement from first-generation antipsychotics. The active molecule was originally found by the US based Bristol-Myers Squibb.
Schizophrenia
The 2016 NICE guidance for treating psychosis and schizophrenia in children and young people recommended aripiprazole as a second line treatment after risperidone for people between 15 and 17 who are having an acute exacerbation or recurrence of psychosis or schizophrenia.[1] A 2014 NICE review of the depot formulation of the drug found that it might have a role in treatment as an alternative to other depot formulations of second generation antipsychotics for people who have trouble taking medication as directed or who prefer it.[2]
Adverse effects
In adults, side effects with greater than 10% incidence include weight gain, headache, akathisia, insomnia, and gastro-intestinal effects like nausea and constipation, and lightheadedness. Side effects in children are similar, and include sleepiness, increased appetite, and stuffy nose. A strong desire to gamble, binge eat, shop, and engage in sexual activity may also occur.
Uncontrolled movement such as restlessness, tremors, and muscle stiffness may occur.
There seems to be no recreational ways for using aripiprazole. It should be also noted that aripiprazole does not work as a viable "tripkiller" for phenethylamine class psychedelics.